BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 22674612)

  • 1. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
    Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
    Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
    Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M
    Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
    Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
    Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
    Pistillucci G; Sciacca V; Ciorra A; Di Palma T; Calabretta F; Lugini A; Rossi R; D'Aprile M; Veltri E
    Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.